Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Gerald W. Prager(Comprehensive Cancer Center Vienna), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya)
Cited by 415
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.4k
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
|Nature reviews. Cancer|2017|1k
Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein
|Blood|2008|60
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
|British Journal of Cancer|2024|12
Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
|Journal of Personalized Medicine|2020|6